Pierre Van Der Bruggen

This inventor holds 73 USPTO granted patents and 2 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Tumor Antigen Research (CPC class 5303). Top assignees: Ludwig Institute for Cancer Research Limited, Oxford University Innovation Ltd, Cornell University. Active years: 1994-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Van Der Bruggen. Retrieved from https://idiyas.com/inventor/pierre-van-der-bruggen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 73 (Patent Applications = 2)

% Patents Active = 86.3

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 582(Granted Patents)

Forward Citations (Not Self Cited) = 504(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Brussels, BE (1994 - 2013)
Chaumont-Gistoux, BE (2015)

Company Filing History:

66 out of 530

Ludwig Institute for Cancer Research Limited

patents

2 out of 484

Oxford University Innovation Ltd

Johannes Gutenberg-Universität Mainz

Ludwig Institute of Cancer Research

Vrije Universiteit Brussel

patents

9. 4 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2015

Loading Chart...

Areas of Expertise:

Tumor Antigens

MAGE Peptides

HLA Class II

T Lymphocytes

Cancer Immunotherapy

Nucleic Acid Molecules

CTL Clones

Peptide Complexes

BAGE Antigens

Individual Therapeutic Vaccination

TAA Detection

HLA Binding

73 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8951747 - Method for modulating activity of T lymphocytes (2015-02-10),

2. 8349558 - Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients (2013-01-08),

3. 7923534 - Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 (2011-04-12),

4. 7488793 - Isolated peptide which binds to HLA-Cw*07 and uses thereof (2009-02-10),

5. 7388072 - MAGE peptides presented by HLA class II molecules (2008-06-17),

6. 7371845 - MAGE-A3 peptides presented by HLA class II molecules (2008-05-13),

7. 7351409 - Tumor antigens and CTL clones isolated by a novel procedure (2008-04-01),

8. RE40089 - Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor (2008-02-18),

9. 7311914 - MAGE-A4 antigenic peptides and uses thereof (2007-12-25),

10. 7252825 - MAGE-3 peptides presented by HLA class II molecules (2007-08-07),

11. 7199231 - Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof (2007-04-03),

12. 7157091 - MAGE-A1 peptides presented by HLA class II molecules (2007-01-02),

13. 7049413 - MAGE-A3 peptides presented by HLA class II molecules (2006-05-23),

14. 7041502 - Isolated peptides which bind to HLA-B18 molecules and uses thereof (2006-05-09),

15. 6946289 - Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof (2005-09-20),

Title: Pierre Van Der Bruggen - A Pioneer in Cancer Immunotherapy

Introduction: Pierre Van Der Bruggen, a renowned inventor based in Brussels, BE, has made significant contributions to the field of cancer immunotherapy with a total of 73 patents to his name. His groundbreaking research focuses on modulating T lymphocyte activity and identifying target antigens for individualized therapeutic vaccinations in cancer patients.

Latest Patents: Van Der Bruggen's latest patents include a method for modulating the activity of T lymphocytes by altering the distance between key receptors on the cell surface. He has also developed a novel approach for detecting individual T-cell reaction patterns against tumor-associated antigens, paving the way for personalized tumor vaccines and therapeutics.

Career Highlights: Throughout his career, Pierre Van Der Bruggen has been associated with prestigious institutions such as the Ludwig Institute for Cancer Research Limited. His innovative work has not only led to the development of cutting-edge patents but has also advanced the field of cancer immunotherapy.

Collaborations: Van Der Bruggen has collaborated closely with esteemed researchers and colleagues, including Thierry R Boon-Falleur and Catia Traversari. Together, they have shared expertise and knowledge to drive forward groundbreaking research in cancer immunotherapy.

Conclusion: In conclusion, Pierre Van Der Bruggen's pioneering work in cancer immunotherapy underscores his commitment to revolutionizing patient care through personalized treatment strategies. His passion for innovation and dedication to improving outcomes for cancer patients have cemented his status as a key figure in the field of medical research.

Profile summary based on public USPTO records.